Core Viewpoint - BeiGene has entered into a royalty purchase agreement with Royalty Pharma, which involves a payment of $885 million for rights to royalties from the sales of the monoclonal antibody Imdelltra outside of China [1] Group 1: Agreement Details - The agreement stipulates that Royalty Pharma will pay $885 million to BeiGene Switzerland upon closing [1] - Royalty Pharma will acquire the rights to a significant portion of the tiered royalties based on the net revenue from Imdelltra sales outside of China [1] - The royalties are calculated as a single-digit percentage of the net revenue, which will be paid by Amgen under the Amgen collaboration agreement [1] Group 2: Additional Rights and Payments - From the closing date until August 25, 2026, BeiGene Switzerland has the option to sell additional royalty rights to Royalty Pharma, potentially earning up to $65 million [1] - If the annual net revenue from Imdelltra outside of China exceeds $1.5 billion, the seller will share a portion of the royalties [1] - BeiGene Switzerland retains other economic benefits under the Amgen collaboration agreement, in addition to the described royalty rights [1]